FDA clears wave of foreign manufacturing plants as COVID-19 concerns continue to grow
U.S. eyes have turned abroad as the coronavirus crisis raises concerns about the safety of the global drug supply. In moves that could shore up confidence, the FDA has given a trio of overseas generics plants the all-clear to produce. Lupin Pharmaceuticals, Dr. Reddy’s Laboratories and Biocon all received clean FDA reports at manufacturing facilities in… Read More »